Cholesterol API Market Size

Cholesterol API Market size was over USD 281.3 million in 2023 and is expected to exceed USD 504.76 million by 2036, witnessing over 4.6% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of cholesterol API is evaluated at USD 291.65 million. The growth of the cholesterol API market is primarily attributed to its being a significant compound for stability of a liposomal membrane formulation which is used in numerous kind of vaccines and drugs delivery systems to get optimum results. For instance, the revolutionary liposome delivery system enables the body to absorb 25 to 100 times more than conventional drug delivery system, making it more effective to cure diseases.

Cholesterol API is frequently used in various types of targeted drugs delivery systems as a very efficient drug carrier. Cholesterol serves as a stabilizing agent in the production of vaccines and medicines. Its lipid nanoparticles are gaining popularity in the pharmaceutical industry as potential drug delivery systems. They are necessary for effective encapsulation and delivery of mRNA to cells. Therefore, increasing demand for novel vaccines and drug delivery methods to tackle the growing prevalence of diseases are anticipated to drive the growth of the cholesterol API market during the forecast period. As per the data provided by the UNICEF, more than 3.8 billion doses of the COVID-19 vaccine have been given till July 2022.